Fresenius Kabi AG is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company offers a wide range of products, including generic drugs, anaesthetics, analgesics, anti-infectives, and medical devices for blood collection and processing. Fresenius Kabi also provides parenteral nutrition products, enteral nutrition products, and various medical devices. Additionally, the company manufactures anti-cancer products, including injectables, oral cytotoxics, cytostatics, intermediates, and active pharmaceutical ingredients for cancer treatment.
mAbxience is a biotechnology company focused on the research, development, and manufacture of biologic products, particularly biosimilar drugs. Established in Europe in 2009, the company operates internationally and has a significant presence in key pharmaceutical markets. With facilities in Spain and Argentina, mAbxience is dedicated to enhancing global healthcare systems by providing high-quality monoclonal antibodies that aid in the treatment and prevention of various diseases. The company has successfully marketed two fully developed biosimilars and currently has four additional products in the development phase, ensuring compliance with regulatory and technical standards in all regions where it operates.
Ivenix
Acquisition in 2022
Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, that specializes in developing advanced intravenous (IV) infusion systems. Founded in 2001 and previously known as Fluidnet Corporation, Ivenix focuses on creating innovative solutions to improve infusion delivery in hospital settings. The company's flagship product is a next-generation infusion management system that employs pneumatic technology to accurately measure and control fluid flow, regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. This system not only simplifies the infusion process but also integrates with clinical information systems, enabling healthcare providers to manage patient infusion data effectively. By aiming to enhance the safety and efficiency of IV therapies, Ivenix is positioned to make a significant impact in the field of medical devices.
Fenwal
Acquisition in 2012
Fenwal is a leading developer and manufacturer of blood transfusion systems, focused on enhancing the safety and availability of blood products. The company specializes in creating and marketing innovative solutions that collect, separate, process, filter, store, and administer whole blood and its components for therapeutic applications. These products play a crucial role in treating a variety of medical conditions, including cancer, kidney failure, hemophilia, immune deficiencies, and infectious diseases. Fenwal serves a diverse clientele, including blood centers, hospital blood banks, and plasma collection centers, significantly impacting the practice of transfusion medicine and ensuring that life-saving therapies are accessible to healthcare professionals and patients worldwide.
Ribbon
Acquisition in 2007
Ribbon is engages in the manufacture and sale of bulk active ingredients for the pharmaceutical industry. It offers betalactam antibiotics with a range of specialized products, such as semi-synthetic penicillins and cephalosporin; and B-Lactamase inhibitor.
Laboratorio Sanderson
Acquisition in 2007
Laboratorio Sanderson is a pharmaceutical company that specializes in the manufacturing, commercialization, and distribution of injectable medications and products for hospitals and healthcare establishments. The company offers a wide range of large-volume parenteral (LVP) solutions, including electrolytes, dextrose, sodium bicarbonate, and products for peritoneal dialysis. Additionally, Laboratorio Sanderson provides small-volume parenteral (SVP) solutions, which encompass antibiotics, analgesics, narcotic-analgesics, hormones, and various other therapeutic agents such as anesthetics, anticoagulants, and antiemetics. These products are designed to meet the needs of both public and private healthcare sectors, facilitating access to essential medications in hospitals, clinics, medical centers, dialysis centers, and pharmacies, both nationally and internationally.
Labesfal - Laboratórios Almiro
Acquisition in 2005
Labesfal - Laboratórios Almiro is manufactures and markets generic and intravenously administered drugs for therapeutic areas. The company’s products are used in the treatment of anti-infective, cardiovascular, analgesic, antipyretic, gastroenterologic, anti-histamine, and central nerves system related diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.